Reverse-Payment Settlement Agreements Roundtable
ABA Antitrust Health Care Chronicle, 2013
21 Pages Posted: 13 Apr 2013 Last revised: 5 May 2015
Date Written: March 20, 2013
This roundtable explores issues presented by "reverse payment" settlements by which brand-name drug companies pay generic firms to delay entering the market. Kent Bernard, Karen Bokat, Michael Carrier, Howard Morse, and Eric Stock explore the history of the settlements, potential legislation, future enforcement efforts, activity in Europe, anticipated market behavior, and predictions about the Court's ruling in FTC v. Actavis.
Keywords: drug patents, reverse payments, settlements, patent, antitrust, pharmaceuticals, Hatch Waxman Act
JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38
Suggested Citation: Suggested Citation